Advertisement

Pharmaceutical & Diagnostic Innovation

, Volume 3, Issue 8, pp 17–21 | Cite as

Corporate Activity — Mergers and Acquisitions

News & View
  • 6 Downloads

Impending mergers and acquisitions

Bausch & Lomb, a global eye health company headquartered in Rochester, NY, has entered into a definitive agreement to acquire a 55% controlling interest in Shandong Chia Tai Freda Pharmaceutical (CTF), the leading ophthalmic pharmaceutical company in China, from Sino Biopharmaceutical. The purchase price of $US200 million in cash represents the equivalent of 18.6 times the Chinese company’s 2004 net earnings. The acquisition will accelerate Bausch & Lomb’s expansion into the rapidly growing ophthalmic pharmaceuticals market in China. In addition, Bausch & Lomb has agreed in principle to a future acquisition of an additional 15% interest in CTF for $US54.5 million. CTF primarily develops, manufactures and markets medications used to treat ocular inflammation and infection, glaucoma and dry eye. Further information is available from http://www.bausch.com/.

Bionutrics of Phoenix, AZ, has entered into an agreement to purchase Florida-based Kirk...

Copyright information

© Adis Data Information BV 2005

Personalised recommendations